Latest Selumetinib Stories
- Array to receive global rights from Novartis to innovative BRAF inhibitor - BOULDER, Colo., Jan. 23, 2015 /PRNewswire/ -- Array BioPharma Inc.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc.
Binimetinib Continues to Advance in Clinical Development BOULDER, Colo., April 29, 2014 /PRNewswire/ -- Array BioPharma Inc.
Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent
6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc.
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas.
- totally perplexed and mixed up.